Affimed (NASDAQ:AFMD) Price Target Cut to $4.00 by Analysts at Stifel Nicolaus

Affimed (NASDAQ:AFMD) had its price target decreased by Stifel Nicolaus from $5.00 to $4.00 in a research note released on Friday morning,Benzinga reports. Stifel Nicolaus currently has a hold rating on the biopharmaceutical company’s stock.

AFMD has been the topic of a number of other research reports. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Affimed in a research note on Friday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Affimed in a research report on Monday, September 9th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $16.00.

Affimed Stock Performance

NASDAQ AFMD opened at $3.48 on Friday. Affimed has a twelve month low of $2.92 and a twelve month high of $8.95. The firm has a 50-day simple moving average of $3.49 and a 200 day simple moving average of $4.51. The company has a current ratio of 2.71, a quick ratio of 2.71 and a debt-to-equity ratio of 0.13.

Affimed (NASDAQ:AFMD) last posted its quarterly earnings results on Thursday, September 5th. The biopharmaceutical company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($1.00) by ($0.09). Affimed had a negative net margin of 7,836.26% and a negative return on equity of 165.35%. The firm had revenue of $0.17 million during the quarter, compared to analyst estimates of $1.67 million. As a group, research analysts forecast that Affimed will post -4.25 EPS for the current fiscal year.

Institutional Investors Weigh In On Affimed

Several institutional investors and hedge funds have recently made changes to their positions in AFMD. Point72 Asset Management L.P. increased its position in shares of Affimed by 4.6% during the 3rd quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock worth $1,152,000 after purchasing an additional 15,108 shares in the last quarter. Jane Street Group LLC acquired a new position in Affimed in the third quarter valued at about $44,000. Intellectus Partners LLC grew its stake in Affimed by 12.2% during the third quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock worth $317,000 after buying an additional 10,250 shares during the last quarter. Choreo LLC acquired a new stake in shares of Affimed during the second quarter worth approximately $54,000. Finally, FMR LLC raised its stake in shares of Affimed by 30.0% in the third quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock valued at $59,000 after acquiring an additional 4,086 shares during the last quarter. Institutional investors and hedge funds own 30.82% of the company’s stock.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.